Application performance of elements in a floating–gate FPAA

Field–programmable analog arrays (FPAAs) provide a method for rapidly prototyping analog systems. Currently available commercial and academic FPAAs are typically based on operational amplifiers (or other similar analog primitives) with only a few computational elements per chip. While their specific architectures vary, their small sizes and often restrictive interconnect designs leave current FPAAs limited in functionality, flexibility, and usefulness. In this paper, we explore the use of floating–gate devices as the core programmable element in a signal processing FPAA. A generic FPAA architecture is presented that offers increased functionality and flexibility in realizing analog systems. In addition, the computational analog elements are shown to be widely and accurately programmable while remaining small in area. 1. LOW–POWER SIGNAL PROCESSING The future of FPAAs lie in their ability to speed the implementatio

Developing large-scale field-programmable analog arrays for rapid prototyping

Field-programmable analog arrays (FPAAs) provide a method for rapidly prototyping analog systems. While currently available FPAAs vary in architecture and interconnect design, they are often limited in size and flexibility. For FPAAs to be as useful and marketable as modern digital reconfigurable devices, new technologies must be explored to provide area efficient, accurately programmable analog circuitry that can be easily integrated into a larger digital/mixed signal system. By leveraging recent advances in floating gate transistors, a new generation of FPAAs are achievable that will dramatically advance the current state of the art in terms of size, functionality, and flexibility

Hydrogen via reforming aqueous ammonia and biomethane co-products of wastewater treatment: environmental and economic sustainability

Green H2 is increasingly viewed as a key energy carrier for the fight against climate change. Wastewater treatment plants (WWTPs) have the unique potential to be centres of renewable H2 generation with the growing availability of two attractive feedstocks: biomethane and ammonia. An innovative and novel method of ammonia recovery from digestate liquor followed by a state-of-the-art H2 production process named NWaste2H2 is demonstrated for a case-study WWTP. The recovered ammonia is used alongside biomethane for H2 production and its diversion from conventional biological treatment has two other crucial benefits, with reductions in both associated electricity demand and emissions of nitrous oxide, an extremely potent greenhouse gas. Process modelling, supported by extensive experiments in a packed-bed reactor at bench-scale, demonstrate the prized capability of simultaneously performing steam methane reforming and ammonia decomposition to generate a H2-rich syngas with yields close to equilibrium values. Greenhouse gas emission abatement from the replacement of diesel buses and reduced N2O emissions from biological treatment could save up to 17.2 kg CO2 equivalent (CO2e) per year for each person served by the WWTP. An in-depth economic study illustrates the ability to achieve a positive net present value with a 10% discount factor as early as 5.8 years when the H2 is prepared and sold to power fuel cell electric buses

Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes

Connective tissue growth factor (CTGF), also known as CCN2, is implicated in fibrosis through both extracellular matrix (ECM) induction and inhibition of ECM degradation. The role of CTGF in inflammation in cardiomyocytes is unknown. In some mesenchymal cell systems, CTGF mediates effects through TGF-β or tyrosine kinase cell surface receptor, TrkA, signalling. In this study, cellular mechanisms by which CTGF regulates pathways involved in fibrosis and inflammation were explored. Murine H9c2 cardiomyocytes were treated with recombinant human (rh)CTGF and ECM formation gene expression: fibronectin, collagen type -I and -III and ECM degradation genes: TIMP-1, TIMP-2 and PAI-1 were found to be induced. CTGF treatment also increased pro-inflammatory cytokines TNF-α, IL-6, MCP-1 and IL-8. CTGF upregulated TGF-β1 mRNA and rapidly induced phosphorylation of TrkA. The CTGF-induced pro-fibrotic and pro-inflammatory effects were blocked by anti-TGF-β neutralizing antibody and Alk 5 inhibitor (SB431542). A specific blocker of TrkA activation, k252a, also abrogated CTGF-induced effects on fibrosis and gene expresison of MCP-1 and IL-8, but not TNF-α or IL-6. Collectively, this data implicates CTGF in effects on pro-fibrotic genes and pro-inflammatory genes via TGF-β pathway signalling and partly through TrkA

Choice in the context of informal care-giving

Extending choice and control for social care service users is a central feature of current English policies. However, these have comparatively little to say about choice in relation to the informal carers of relatives, friends or older people who are disabled or sick. To explore the realities of choice as experienced by carers, the present paper reviews research published in English since 1985 about three situations in which carers are likely to face choices: receiving social services; the entry of an older person to long-term care; and combining paid work and care. Thirteen electronic databases were searched, covering both the health and social care fields. Databases included: ASSIA; IBSS; Social Care Online; ISI Web of Knowledge; Medline; HMIC Sociological Abstracts; INGENTA; ZETOC; and the National Research Register. The search strategy combined terms that: (1) identified individuals with care-giving responsibilities; (2) identified people receiving help and support; and (3) described the process of interest (e.g. choice, decision-making and self-determination). The search identified comparatively few relevant studies, and so was supplemented by the findings from another recent review of empirical research on carers' choices about combining work and care. The research evidence suggests that carers' choices are shaped by two sets of factors: one relates to the nature of the care-giving relationship; and the second consists of wider organisational factors. A number of reasons may explain the invisibility of choice for carers in current policy proposals for increasing choice. In particular, it is suggested that underpinning conceptual models of the relationship between carers and formal service providers shape the extent to which carers can be offered choice and control on similar terms to service users. In particular, the exercise of choice by carers is likely to be highly problematic if it involves relinquishing some unpaid care-giving activities

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review

Sodium‐glucose co-transporter 2 (SGLT2) inhibitors have recently emerg ed as an effective means to protect kidney function in people with type 2 diabetes and chronic kidney disease (CKD). In this review, we explore the role of SGLT2 inhibition in these individuals. SGLT2 inhibitors specifically act to inhibit sodium and glucose reabsorption in the early proximal tubule of the renal nephron. Although originally developed as glucose-lowering agents through their ability to induce glycosuria, it became apparent in cardiovascular outcome trials that the trajectory of kidney function decline w as significantly slowed and the incidence of serious falls in kidney function was reduced in participants receiving an SGLT2 inhibitor. These observations have recently led to spe cific outcome trials in participants with CKD, including DAPA-CKD, CREDENCE and EMPA-KIDNEY, and real-world studies, like CVD-REAL-3, that have confirmed the observation of kidney benefits in this setting. In response, recent KDIGO Guidelines have recommended the use of SGLT2 inhibitors as first-line therapy in patients with CKD, alongside statins, renin–angiotensin– aldosterone system inhibitors and multifactorial risk factor management as indicated. However, SGLT2 inhibitors remain significantly underutilized in the setting of CKD. Indeed, an inertia paradox exists, with patients with more severe disease less likely to receive an SGLT2 inhibitor. Concerns regarding safety appear unfounded, as acute kidney injury, hyperkalaemia, major acute cardiovascular events and cardiac death in patients with CKD appear to be lower following SGLT2 inhibition. The first-in-clas s indication of dapagliflozin for CKD may begin a new approach to managing kidney disease in type 2 diabetes